Psychedelic Stocks: Why Your Investment Portfolio Should Be Teeming With Them

This may sound unbelievable, but, despite the raging COVID-19 pandemic, great investment opportunities are still out there. By investment, we are not referring to companies which specialize in bulk-packaging toilet paper or churning out millions of gallons of sanitizer. Psychedelic medicine stocks are what we are talking about, and here are some compelling reasons why your investment portfolio needs to have these medicines.

You’d Be Getting in Early

Lots of people who invested in marijuana stocks are regretting their decision for one key reason; they joined the fray late in the game when marijuana stocks had nearly peaked, and the ongoing market correction is giving them sleepless nights.

In contrast, there couldn’t be a better time to acquire psychedelic medicine stocks. The industry is just taking off, and it is even hard to come up with an accurate estimate of how big it will get. However, there is general consensus that the sector has immense potential, so wouldn’t this be the best time to get in and ride the wave all the way to the top?

Effects of the Coronavirus Pandemic

Psychedelic medicine is largely seen as an industry which will revolutionize how mental health conditions are treated, and whichever way you look at the COVID-19 crisis, mental health issues are written all over it from the depression due to job losses, to the emotional distress linked to losing loved ones and not having a chance to be at their bedside while they passed, and even the mental health complications resulting from being alone as you self-isolate.

All these conditions create a perfect time for mental health problems to skyrocket, and that means psychedelic medicine has come at just the right time to steady the ship. Seen this way, investing in the sector becomes a no-brainer.

It Isn’t Recreational

Psychedelic medicine has got the nod from regulators like Health Canada and the U.S. Food and Drug Administration largely because of its demonstrated therapeutic potential. The fact that psychedelic companies like Pure Extracts Corp. aren’t looking to make these substances recreational means that all the politics that goes into other controversial substances like marijuana is absent in the case of psychedelics.

Getting a bunch of these stocks is therefore financially sound, and it also makes a lot of moral sense since you will be contributing to making medicine available to people who have very few options of getting a lasting solution.

Public Sentiment is Shifting

Psychedelics still have stigma attached to them, but with regulators giving them the nod, it will not take long for these substances to go mainstream. After all, the approval given by the FDA and other such regulators clearly signifies that the medicines are safe and effective, so members of the public will have no reason to object.

The psychedelic pie can only get bigger as perceptions shift even more, and since there are huge barriers to entry, investors who put their money into the industry are likely to reap big. Your task is to do your homework and choose those specific stocks which meet your investment criteria.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.